{
    "organizations": [],
    "uuid": "b6d3a83f9244106ee08047dc033f103fe709afe2",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-puma-biotechnology-requests-ema-to/brief-puma-biotechnology-requests-ema-to-re-examine-the-negative-opinion-issued-by-chmp-for-maa-for-neratinib-idUSFWN1QQ0AT",
    "ord_in_thread": 0,
    "title": "BRIEF-Puma Biotechnology Requests EMA To Re-Examine the Negative Opinion Issued By CHMP For MAA For Neratinib",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 8 (Reuters) - Puma Biotechnology Inc:\n* PUMA BIOTECHNOLOGY SAYS ‚ÄçGIVEN WRITTEN NOTICE TO EMA TO REQUEST RE-EXAMINATION OF NEGATIVE OPINION ISSUED BY CHMP IN FEB 2018 FOR MAA FOR NERATINIB Source text for Eikon: ( bit.ly/2G6kIc2 ) Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles.",
    "published": "2018-03-08T19:41:00.000+02:00",
    "crawled": "2018-03-09T14:32:51.008+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "puma",
        "biotechnology",
        "inc",
        "puma",
        "biotechnology",
        "say",
        "written",
        "notice",
        "ema",
        "request",
        "negative",
        "opinion",
        "issued",
        "chmp",
        "feb",
        "maa",
        "neratinib",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "standard",
        "thomson",
        "reuters",
        "trust",
        "principle"
    ]
}